News blog


  • BY: Andrew Hore |
  • POSTED: 15/03/2010 |

Skin treatments developer Syntopix is raising up to 2m at 67p a share.

Syntopix will receive 1.91m after expenses and this will be used to finance further studies of its compounds. Further human use studies will be carried out this year after initial results were positive.

Syntopix had net cash of 396,000 at the end of January 2010. The six month cash outflow from operations was 498,000.

IP Group and its offshoots will increase their stake from 24.3% to 27.9%. Directors will own just under 10% of Syntopix.

At 73p a share, Syntopix is valued at 5.63m.

© 2023 Aim Micro. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Browse by issue
All issues
Popular tags
All tags

betbrokers, financial, gold, health, leisure, media, mobile, resources, services, technology

AIM Micro feeds

Keep up to date with articles published at Subscribe to AIM Micro RSS Feeds